Boston Scientific Q1 Sales Climb 11.6% to $5.2B with $0.90 EPS
Boston Scientific reported Q1 net sales of $5.203 billion, up 11.6% reported and 9.4% operational and organic, with GAAP EPS of $0.90 and adjusted EPS of $0.80. The company announced positive CHAMPION-AF and HI-PEITHO clinical trial results and completed the acquisition of Valencia Technologies Corporation.
1. First Quarter Financial Results
Boston Scientific generated net sales of $5.203 billion in Q1, up 11.6% reported and 9.4% operational and organic year-over-year. GAAP net income reached $1.341 billion, or $0.90 per share, with adjusted EPS of $0.80, at the top of its guidance range.
2. Segment and Regional Performance
Cardiovascular net sales rose 13.5% reported (11.2% operational), while MedSurg grew 7.8% reported (5.7% operational). Regionally, Asia-Pacific led with 14.7% reported growth, followed by Latin America and Canada at 19.0% reported, Europe, Middle East and Africa at 10.1%, and the U.S. at 10.9%.
3. Clinical Trial Outcomes and Approvals
The CHAMPION-AF study of the WATCHMAN FLX device met all primary and secondary endpoints, showing superior bleeding risk reduction versus anticoagulants. The HI-PEITHO trial demonstrated the EKOS system’s superiority in intermediate-risk pulmonary embolism, and China’s regulator approved the OPAL HDx mapping system.
4. Strategic Acquisitions and Board Elections
The company completed the acquisition of Valencia Technologies, developer of the eCoin system for urinary incontinence, and received FDA 510(k) clearance for the Asurys fluid management system. Cathy Smith and Christophe Weber were elected to the board of directors.